Latest news

We are pleased to announce that we have now completed our Pilot BE program for Palbociclib Film-coated Tablets, which is being developed in collaboration with our oncology specialty, sister company, forming...

Adalvo is delighted to announce the successful DCP closure of our Dimethyl Fumarate 120mg, 240mg hard capsules in Europe.

Adalvo is very proud to announce that our Phase III Study for Pregabalin ER tablets has been completed successfully. The study was conducted with a patient population of over 450...

Adalvo is now able to offer over 100 tailor-made products to our partners. As part of our growth journey, our focus has always been to bring high-value, differentiated products, covering...

We are pleased to announce that we have now completed our Pivotal BE program for Tafamidis Meglumine Soft Gel Capsules 20mg.

Adalvo is pleased to announce that our dossier for Apremilast Film-Coated Tablets is complete and our DCP submission is scheduled for January 2023.

We are pleased to announce that we have now completed our Pivotal BE program for Macitentan 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic...

Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked for the15th July 2022.

We are pleased to announce the successful progression of Cladribine, which is being developed based on the reference brand Mavenclad (Merck) and is indicated in the treatment of Multiple Sclerosis....

One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are now developing...

Adalvo is delighted to announce the successful EU DCP closure of our Enzalutamide Soft Gel Capsules. We believe to be the first Company to receive an EU approval,  and with this...

The Consortium jointly, through Aztiq II HoldCo, has acquired a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholder in Adalvo. The Consortium’s collective industry experience,...

Adalvo is one of the few companies who can offer a comprehensive diabetes portfolio covering small molecule oral treatments and complex peptide injectables. We understand that diabetes is becoming one of the fast-growing diseases, and...

We are proud to announce that our distinguished hybrid / 505(b)(2) asset Gralise® has reached an advanced stage and that Adalvo will move into launch in Q1 2023. With this achievement we add a...

As we strengthen our injection product pipeline, we are pleased to provide a status update on our development of Dalbavancin. The development of this complex niche generic is progressing very...

As we continue to deliver on our brand promise of being the preferred partner and setting a new standard for the future of Pharma, Adalvo provides various solutions and differentiated...

Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked and the submission will be completed in July 2022.

We are pleased to announce that we have now completed our Pivotal BE program for Apremilast Film-Coated Tablets. This product has been developed in collaboration with one of our strategic...

We are pleased to provide a status update on our development of Eribulin injection 0.44mg/ml. The development of this product is progressing very well; our dossier will be available for...

We are pleased to announce that, following the successful completion of our ANDA for Midostaurin Capsules 25mg in the US, we have now completed our Pivotal BE program in Europe....

We are pleased to announce that our US dossier of Semaglutide 1.34mg/ml pre-filled pen is ready and available for licensing in Ex-US markets. We will now move full steam...